Protara Announces Pricing of $75 Million Public Offering

Protara Announces Pricing of $75 Million Public Offering




Protara Announces Pricing of $75 Million Public Offering

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,043,479 shares of its common stock at a price to the public of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares in the offering are being sold by Protara. The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and offering expenses payable by Protara and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 8, 2025, subject to satisfaction of customary closing conditions. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.

J.P. Morgan, TD Cowen and Piper Sandler are acting as joint book-running managers. LifeSci Capital is acting as a lead manager of the offering. H.C. Wainwright & Co. is acting as a manager of the offering.

The shares of common stock will be issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-275290) that was declared effective on November 14, 2023 by the U.S. Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus supplement and the accompanying prospectus. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website, at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from the offices of J.P. Morgan Securities LLC, 270 Park Avenue, New York, New York 10017, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at TDManualrequest@broadridge.com; or Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding the timing, size and completion of the public offering as well as the expected use of proceeds related thereto are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: Protara’s ability to complete the offering on the proposed terms, or at all, and Protara’s expectations related to the use of proceeds from the offering. Additional important factors to be considered in connection with forward-looking statements, including additional risks and uncertainties, are described more fully under the caption “Risk Factors” and elsewhere in Protara’s filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

Company Contact:
Justine O’Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

Sapu Nano Announce Deciparticle™ Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

Sapu Nano Announce Deciparticle™ Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine




Sapu Nano Announce Deciparticle™ Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

San Diego, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) — Sapu Nano today announced new biomarker data identifying a molecular signature that predicts sensitivity to Sapu003, the company’s intravenous Deciparticle formulation of everolimus. These data will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) Dec 9-12. This work describes the first prospective biomarker framework for intravenous everolimus and establishes a foundation for mTOR therapy targeted to the patient populations most likely to benefit.

The analysis, which evaluated more than 9,000 patient tumor samples across 20 cancer types, revealed that tumors exhibiting a High-RICTOR / Low-RPTOR gene-expression pattern show a significantly greater dependency on mTOR signaling and are therefore, more likely to respond to potent mTOR inhibition delivered by IV Sapu003.

The biomarker analysis demonstrated that:

  • Tumors with elevated RICTOR (mTORC2 activation) and suppressed RPTOR (limited mTORC1 scaffolding) show heightened reliance on mTORC2-AKT survival signaling.
  • These tumors exhibit increased glycolytic flux, elevated metabolic stress markers, and reduced compensatory feedback, making them vulnerable to systemically distributed everolimus.
  • This phenotype/genotype was strongly enriched in:
    • HR+/HER2- breast cancer
    • Lung adenocarcinoma
    • Gastric cancer
    • Renal cell carcinoma
    • Ovarian cancer
    • AML and T-cell malignancies

Across multiple datasets, patients with this signature had significantly worse survival with standard therapy, but showed predicted sensitivity to Sapu003.

This enables, for the first time, biomarker-enriched patient selection for an mTOR inhibitor.

“Up to now mTOR inhibitor therapy has lacked an empirical patient selection strategy beyond tumor type,” said Dr. Seymour Fein, Chief Medical Officer of Sapu Nano. “The High-RICTOR/Low-RPTOR signature gives us, for the first time, a molecular map of which patients are most likely to benefit. The potential for targeting a more sensitive patient population combined with the consistent pharmacokinetic profile of Sapu003 administered intravenously creates an entirely new therapeutic opportunity for mTOR-driven cancers.”

About Sapu003

Sapu003 is a novel intravenous nanoparticle formulation of everolimus engineered using Sapu Nano’s proprietary Deciparticle technology. It is designed to overcome the poor bioavailability, intestinal toxicity, and variable patient exposure seen with oral everolimus while enabling reliable, predictable weekly IV dosing.

About the Deciparticle Platform

The Deciparticle platform is a proprietary nanotechnology engineered to encapsulate hydrophobic molecules as uniform, sub-20 nm nanoparticles for intravenous administration. The platform improves systemic exposure, reduces GI deposition, and supports precision delivery while maintaining manufacturability at clinical scale.

About Sapu Nano

Sapu Nano is a clinical-stage biotechnology company developing Deciparticle nanomedicine therapeutics designed to optimize the delivery of hydrophobic oncology agents and peptide-based therapeutics. The company operates an integrated ISO-5 cGMP manufacturing facility supporting rapid progression from formulation to clinical trial supply.

For more information, visit www.sapunano.com.

Investor & Media Contact
Sapu Nano (US) LLC
Investor Relations
ir@sapubio.com

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025




ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases

36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks

Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate

Enrollment and follow-up continue in 1L EGFR PACC patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial

Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET

SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. Data in previously treated NSCLC patients with EGFR atypical mutations were presented at a mini-oral session, and the presentation can be found in the publication section of ORIC’s website here. In addition, compelling preliminary data in 1L NSCLC patients with EGFR P-loop and alpha C-helix compressing (PACC) mutations were disclosed.

“Enozertinib was purposefully designed to be highly brain-penetrant and exquisitely selective in order to address the limitations of available therapies and potentially drive differentiated durability. These data provide clinical support for this design approach, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR PACC mutations,” said Pratik S. Multani, M.D., chief medical officer. “The profile we have seen with enozertinib compares favorably to other investigational therapies and continues to support enozertinib’s best-in-class potential.”

Enozertinib Phase 1b Trial Design
Enozertinib is being evaluated in a Phase 1b trial in patients with locally advanced or metastatic NSCLC with EGFR atypical mutations. Notably, enrollment allows patients with active untreated brain metastases. Prior therapies in previously treated patients include chemotherapy and EGFR targeted therapies. The primary endpoint of the trial is to determine the recommended Phase 2 dose (RP2D), and secondary endpoints include investigator-assessed objective response rate (ORR), disease control rate (DCR), and safety.

Previously Treated NSCLC Patients with EGFR Atypical Mutations
As of the August 29, 2025 cutoff date, 47 patients were dosed — 25 patients received 80 mg QD oral enozertinib and 22 patients received 120 mg QD. Patients were heavily pretreated, having received a median of 2 prior therapies, with 81% of patients having received a prior EGFR targeted therapy, including osimertinib and afatinib. Brain metastases were present in 55% of patients at baseline, including those with active brain metastases.

Preliminary Safety Analysis
Enozertinib was well tolerated with mostly Grade 1 or 2 treatment-related adverse events (TRAEs) and no significant off-target toxicities. Most frequent TRAEs included diarrhea, paronychia, and stomatitis. There were no treatment discontinuations related to TRAEs. High rates of early dose reductions occurred in the 120 mg cohort compared to the 80 mg cohort, such that most patients received an effective dose of 80 mg QD.

22 patients with PACC mutations were efficacy evaluable, all receiving an effective dose of 80 mg QD, consisting of 12 patients from the 80 mg cohort and 10 patients from the 120 mg cohort who underwent early dose reduction.

Preliminary Activity Analysis
In the 22 efficacy evaluable patients with PACC mutations, enozertinib demonstrated strong systemic and CNS antitumor activity.

  • 36% confirmed ORR and 91% DCR, with comparable rates in patients with brain metastases at baseline
  • Responses observed across a wide range of EGFR PACC mutations including in the most prevalent mutations (i.e., G719X, S768I), and in a broad spectrum of PACC complex mutations
  • As of the data cutoff (at a median follow-up of over 32 weeks), 75% of responders remained on treatment

1L NSCLC Patients with EGFR PACC Mutations (Preliminary)
As of the November 18, 2025 cutoff date, 10 efficacy evaluable patients were dosed with 80 mg QD oral enozertinib. 60% of these patients had brain metastases at baseline, all of which were active and untreated. The safety profile to date in this cohort of patients is in line with the safety profile at the 80 mg QD dose level in other cohorts. Enozertinib demonstrated strong preliminary systemic and CNS activity, including 80% ORR and 100% intracranial ORR in patients with measurable CNS disease (investigator-assessed by RECIST).

Next Steps 
Based on these data, 80 mg QD oral enozertinib has been selected as the dose for potential Phase 3 development. Enrollment and follow-up continues in 1L EGFR PACC patients with the next update expected in mid-2026, ahead of initiation of a potential Phase 3 trial.

Conference Call and Webcast Details
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential best-in-class profile of enozertinib, including antitumor activity that exceeds competitor benchmarks; clinical outcomes from studies of enozertinib, which may materially change as patient enrollment continues or more patient data become available; the development plans and timelines for enozertinib; the potential advantages of enozertinib; and statements by the company’s chief medical officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on November 13, 2025, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia




Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia

Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months

PRINCETON, N.J. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) — Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from the phase I/II Transtar102 trial of osemitamab plus nivolumab and CAPOX in first-line Gastric/Gastroesophageal Junction (G/GEJ) cancer. The new findings were showcased in a poster presentation (Abstract #299P) at the ESMO Asia Congress 2025 in Singapore.

This new analysis reinforces the encouraging clinical benefit of the osemitamab triple combination regimen in the ongoing study. In the 26 patients with CLDN18.2 expression ≥40%, ≥2+ and known PD-L1 CPS, the median PFS reached 16.6 months, with an ORR of 68% and a median DoR of 18 months at a 25.8-month median follow-up. Notably, better PFS outcomes were observed in patients with higher CLDN18.2 expression compared to lower CLDN18.2 expressors in both PD-L1 CPS<1 and ≥1 subgroups, which indicated the potential treatment benefit of osemitamab is consistent regardless of PD-L1 expression.

The safety profile was similar to that previously presented at ASCO 2025.

“The exploratory efficacy analysis continues to show promising clinical benefit with osemitamab when combined with standard-of-care therapy,” said Professor Lin Shen, Director, Department of Gastrointestinal Oncology and Phase I Clinical Trial Center at Peking University Cancer Hospital; and Principal Investigator of the trial. “The consistency of benefit across different PD-L1 subgroups is particularly noteworthy and suggests that this regimen may offer meaningful improvement for a broad population of patients with advanced G/GEJ cancer.”

“We are encouraged to see the continued strength of the clinical signals in this study, which reinforce the potential of osemitamab to deliver meaningful benefit to patients in need of more effective treatment options,” said Dr. Charlie Qi, Executive Vice President, Head of Global Clinical Development at Transcenta. “Further, these updated data continue to demonstrate that the combination of osemitamab with nivolumab and CAPOX is safe and well tolerated as a first-line regimen for patients with advanced G/GEJ cancer.”

About Osemitamab
Osemitamab is a high affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (“ADCC”). It has shown potent anti-tumor activities in tumor xenograft models. Osemitamab is the second CLDN18.2 targeting antibody being developed globally. Osemitamab was generated using Transcenta’s Immune Tolerance Breaking Technology (IMTB) platform. Osemitamab kills CLDN18.2 expressing tumor cells by mechanisms of ADCC. Leveraging advanced bioprocessing technology, the fucose content of osemitamab was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of osemitamab. Osemitamab has been granted Orphan Drug Designation in the U.S. by FDA for the treatment of patients with gastric or gastroesophageal junction (G/GEJ) and pancreatic cancer.

About Transcenta Therapeutics
Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.

Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in China, U.S. and Europe. Transcenta is developing a diverse pipeline of more than a dozen novel biologic therapies for oncology and selected non-oncology indications including bone and kidney disorders.

For more information, please visit www.transcenta.com and https://www.linkedin.com/company/transcenta. For inquiries regarding capital cooperation opportunities, please contact us at ir@transcenta.com

Contacts:
PR@transcenta.com
IR@transcenta.com
BD@transcenta.com

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA




Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct a global registrational Phase III study (POLARIS-1; NCT06051409) of its compound under investigation, olverembatinib, in combination with chemotherapy for the treatment of newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). As the second global registrational Phase III study of olverembatinib that has been cleared by regulators in the US and Europe, the POLARIS-1 study is simultaneously enrolling patients across trial centers in multiple countries in order to accelerate olverembatinib’s path to registration worldwide, particularly in the US and European markets.

The POLARIS-1 trial is a global, multicenter, randomized controlled, open-label Phase III study designed to evaluate the efficacy and safety of olverembatinib in combination with chemotherapy in newly diagnosed patients with Ph+ ALL. The POLARIS-1 study was also initiated in China after it was cleared by the China Center for Drug Evaluation (CDE) in 2023. 

The POLARIS-1 study is set to release its first dataset at the upcoming 2025 American Society of Hematology (ASH) Annual Meeting. Data disclosed in the ASH 2025 abstract showed that among treatment-naïve patients with Ph+ ALL who received olverembatinib in combination with low-intensity chemotherapy, the minimal residual disease (MRD) negativity rate and the molecular MRD-negative complete response (CR) rate at the end of three treatment cycles both reached approximately 65%, which significantly improved the efficacy reported for other drugs in the same class. Notably, the combination regimen also demonstrated favorable clinical benefit in patients with certain high-risk subtypes such as those harboring the IKZF1plus mutation. In addition, the combination regimen demonstrated a favorable safety profile, with a low incidence of adverse events which were mostly manageable.

Accounting for 20%-30% of all ALL cases in adults, Ph+ ALL is commonly associated with a disproportionately high incidence in the elderly population, a high relapse rate, short disease-free survival, and poor prognosis. Prior to the introduction of tyrosine kinase inhibitors (TKIs), chemotherapy-only treatment delivered a five-year overall survival (OS) rate of less than 20%. The clinical adoption of TKIs has resulted in a new clinical paradigm for patients with Ph+ ALL. However, first- and second-generation TKIs have considerable limitations in the treatment of Ph+ ALL.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, “Clearances from the U.S. FDA and the EMA for this global registrational Phase III study mark a significant step forward in the global development of olverembatinib in Ph+ ALL. Fulfilling our mission of addressing unmet clinical needs in China and around the world, we will press ahead with the clinical development of olverembatinib in Ph+ ALL and strive to bring a new treatment option to patients around the world as soon as possible.”

Developed by Ascentage Pharma, olverembatinib is an orally administered, third-generation TKI and the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics. Olverembatinib has already been approved in China in multiple indications in drug-resistant chronic myeloid leukemia (CML) and all of the approved indications are now covered by the China National Reimbursement Drug List (NRDL). Being developed for the treatment of Ph+ ALL, olverembatinib has received consecutive recommendations in the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Hematologic Malignancies and a Breakthrough Therapy Designation by the China CDE.

On June 14, 2024, Ascentage signed an exclusive option agreement to enter into an exclusive license agreement with Takeda for olverembatinib. In the event that Takeda exercises the option, Takeda would license the global rights to develop and commercialize olverembatinib in all territories outside of, among others, mainland China, Hong Kong, Macau, and Taiwan, China.

* Olverembatinib is currently under investigation and has not yet been approved by the FDA in the US.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.

The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting a US FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.

The Company’s second approved product, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the US FDA-cleared GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the US FDA, the EMA of the EU, and China CDE.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.

These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations:
Stella Yang
Ascentage Pharma
Stella.Yang@ascentage.com
+1 (301) 792-6286

Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282

Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012

ImPact Biotech Presents Updated Preliminary Data from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at SUO 2025

ImPact Biotech Presents Updated Preliminary Data from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at SUO 2025




ImPact Biotech Presents Updated Preliminary Data from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at SUO 2025

– Complete response (CR) observed in 70% (35/50) of patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP)

– Initial durability data shows all patients (100%) who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the data cutoff date 

– Padeliporfin VTP treatment continues to be safe and well-tolerated, establishing profile consistent with prior results alongside additional follow-up in MTP

– Complete enrollment in study expected in Q1 2026, with topline data anticipated in the first half of 2026

TEL AVIV, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced updated interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment of patients with low-grade upper tract urothelial cancer (UTUC). These data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025) on December 4, 2025, in Phoenix, Arizona.

“We are pleased to share updated data from the Phase 3 ENLIGHTED study, which further strengthen Padeliporfin VTP’s profile as a next-generation treatment option for LG UTUC with potential to improve long-term patient outcomes,” said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. “We continue to see significant efficacy, with complete responses achieved in 70% of patients, and consistent established safety with similar observations to date. Moreover, this first look at the program’s durability profile shows complete responses were sustained in patients for over twelve months following the Maintenance Treatment Phase, and we are excited to advance this minimally invasive, organ-sparing therapy further towards our goal of transforming the treatment landscape for patients with unresectable solid tumors. Padeliporfin VTP is well-positioned to address the current unmet medical need in LG UTUC as we look to complete enrollment by Q1 2026 and report topline data in the first half of 2026.”

Key results from the preliminary analysis of the Phase 3 ENLIGHTED study of Padeliporfin VTP:

As of July 28, 2025, the data cut-off for the poster presentation at SUO 2025, 68 patients had begun treatment, of which 50 had completed ITP and were evaluable for efficacy.

Clinical Profile:

  • Overall response rate 88%.
  • 35 of the 50 (70%) response-evaluable patients achieved a CR at the end of ITP.
  • 9 of the 50 (18%) response-evaluable patients achieved a partial response (PR) at the end of ITP.

Durability Profile:

  • All patients (100%) who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the data cutoff date with additional patients progressing in the MTP that have yet to complete the 12-month evaluation period.

Safety and Tolerability Profile:

  • Padeliporfin VTP was well-tolerated with a safety profile consistent with the previous data obtained from the Phase 1 study and previously announced preliminary Phase 3 results.
  • Adverse events (AEs): the majority of treatment-emergent adverse events (TEAEs) were mild or moderate, primarily related to the ureteroscopic procedure, and resolved within a few days. One Grade 3 serious adverse event related to VTP treatment was reported and resolved within two days. No TEAEs of special interest were reported and no TEAE led to discontinuation of the study treatment.

ImPact continues to recruit for the ENLIGHTED study and expects to complete enrollment in the first quarter of 2026. The company anticipates the presentation of topline ENLIGHTED data in the first half of 2026.

Poster & Session Details:

Poster Title: ENLIGHTED Phase 3 study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC)
Presenter: Vitaly Margulis, M.D., Professor of Urologic Oncology, University of Texas Southwestern
Medical Center
Poster Number: 166
Session Title: SUO Top Abstract Tour
Session Date & Time: December 4, 2025, 4:30 PM MST

About ENLIGHTED
The Phase 3 ENLIGHTED study is a single arm, non-randomized, open-label, pivotal trial evaluating Padeliporfin VTP for the treatment of low-grade UTUC. Across 29 clinical sites globally, ImPact is targeting enrollment of up to 100 patients with new or recurrent low-grade, non-invasive UTUC of the kidney or ureter. The study consists of two parts – an Induction Treatment Phase (ITP) and Maintenance Treatment Phase (MTP) – across which Padeliporfin, a photosensitizing drug, is administered intravenously and VTP therapy is performed, via an outpatient endoscopy which applies a laser fiber illumination for 10 minutes in the proximity of the tumor, leading to local activation of Padeliporfin in the tumor. ITP consists of one-to-three treatments with VTP therapy at four-week intervals or until a complete response (CR) is achieved; MTP follows with standard-of-care treatment alongside VTP therapy administered every three months for up to 12 months. The study’s primary objective is to assess the response rate to Padeliporfin VTP treatment at the end of ITP, with secondary objectives evaluating safety, tolerability and duration of response.

About ImPact Biotech
ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: www.impactbiotech.com and the ENLIGHTED clinical trial website (for the US): https://www.enlighted-study.com.

Contacts

Global Head of Business Development
Guy Schmidt
guy.schmidt@impactbiotech.com

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor




Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the successful completion of its pre-NDA (New Drug Application) meeting with the FDA, including receipt of written feedback and an in-person meeting. Praxis has gained alignment from the agency on the content of the NDA and expects to complete its NDA submission in early 2026.

“We are very pleased with the collaborative discussions we recently had with the FDA and remain on track to submit Praxis’ first NDA in early 2026. Building on the strong momentum from the positive Essential3 program, where ulixacaltamide demonstrated statistically significant and clinically meaningful improvements in daily functioning, the FDA feedback moves us closer to delivering a much-needed therapy to the millions of people living with essential tremor who currently lack effective and safe treatment options,” said Marcio Souza, president and chief executive officer.

About Essential Tremor (ET)

Essential tremor is the most common movement disorder, affecting roughly seven million people in the United States alone, representing a multi-billion-dollar commercial opportunity. ET is characterized by involuntary rhythmic movement in the upper limbs, with or without tremor in other body locations such as the head, vocal cords, or legs. These tremors significantly disrupt daily living and are progressive in nature, with increases in tremor severity and amplitude commonly observed over the course of the disease. Propranolol, a beta-blocker, is the only approved pharmacotherapy for ET, offering limited efficacy and poor tolerability and is also contraindicated for comorbidities that affect a significant share of the ET population. Other beta blockers and anti-convulsants are used off-label, though similarly are characterized by limited efficacy and tolerability. The vast majority of patients are left without a treatment option, with an estimated minimum of 2 million patients seeking treatment. In a patient survey, up to 77% of patients felt their ET is inadequately controlled and up to 50% of patients are not receiving treatment. Similarly, U.S. neurologists surveyed indicated that 85% of their visits are for patients seeking treatment, and 40% of their patients are not receiving any treatment. These findings underscore the need for more effective treatments for ET.

About Ulixacaltamide

Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity. Ulixacaltamide is the most advanced program within Praxis’ Cerebrum™ small molecule platform.

About Praxis  
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on FacebookInstagramLinkedIn and Twitter/X.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including, without limitation, statements regarding the development of Praxis’ product candidates and the anticipated timing of regulatory submissions and interactions, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis’ programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2024 and as updated in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as well as other filings made with the Securities and Exchange Commission. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

CONTACT: Investor Contact: 
Praxis Precision Medicines 
investors@praxismedicines.com 
857-702-9452 
 
Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Capricor Therapeutics Announces Proposed Public Offering of Common Stock




Capricor Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the proposed public offering.

The Company intends to use the net proceeds from the proposed offering for the continued development of its product candidates, manufacturing of its product candidates, working capital and general corporate purposes.

The securities are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-290179) that was originally filed with the Securities and Exchange Commission (“SEC”) on September 10, 2025 and declared effective on September 23, 2025. The offering is being made only by means of a prospectus and related prospectus supplement. The preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained from Piper Sandler & Co. at 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@psc.com; and Oppenheimer & Co. Inc. at Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel’s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the proposed public offering of common stock and the anticipated use of proceeds therefrom and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including, but not limited to, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed offering. There can be no assurance that we will be able to complete the proposed public offering on the anticipated terms, or at all. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025, and in Capricor’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed with the Securities and Exchange Commission on November 10, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

GATC Health to Host Virtual KOL Event to Discuss Derisq™ AI Report: Predictive, Detailed Risk Assessment of Drug Candidates, on December 10, 2025

GATC Health to Host Virtual KOL Event to Discuss Derisq™ AI Report: Predictive, Detailed Risk Assessment of Drug Candidates, on December 10, 2025




GATC Health to Host Virtual KOL Event to Discuss Derisq™ AI Report: Predictive, Detailed Risk Assessment of Drug Candidates, on December 10, 2025

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, announced that it will host a virtual key opinion leader (KOL) event on Wednesday, December 10, 2025 at 1:00 PM ET/10:00 AM PT. The event will feature Lin Yu, PhD (Former Managing Director, Oppenheimer Healthcare Investment Banking), Tomas Philipson, PhD (Former Acting Chairman, Council of Economic Advisers, Executive Office of the President), and Greg Sarafin (Former Global Vice Chair, Ernst & Young), who will join members of company management Rahul Gupta, MD, MPH, MBA, FACP (Former Director, National Drug Control Policy; President, GATC Health) and Tyrone Lam (Chief Business Officer, GATC Health), to discuss the company’s Derisq™AI Report providing predictive, detailed risk assessment for drug candidates. To register, click here.

The Derisq AI Report uses GATC Health’s proprietary AI platform to provide biopharma leaders and investors with an objective, data-driven assessment of a drug candidate’s likely endpoint performance—streamlining pipeline prioritization, optimizing trial design, and revealing risks that traditional approaches may overlook. It delivers validated, actionable insights on drug safety, efficacy, and off-target risks, revolutionizing how the industry evaluates therapeutic potential. This underlying technology has been independently verified by University of California Irvine, demonstrating 91% specificity and 86% sensitivity.

KOLs and members of company management will provide an overview of Derisq’s elevated strategic planning, and how it empowers biotech leaders and investors to make informed decisions with confidence long before committing to clinical trials.

A live question and answer session will follow the formal presentations.

About Rahul Gupta, MD, MPH, MBA, FACP
Rahul Gupta, MD, MPH, MBA, FACP, was appointed as President of GATC Health in February 2025. He served as the first medical doctor to serve as the Director of National Drug Control Policy and lead the Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President, from 2021 until January 2025. ONDCP coordinates the nation’s $43 billion drug budget and federal policies, including prevention, harm reduction, treatment, recovery support, and supply reduction. A board-certified internist, Dr. Gupta has been a practicing primary care physician for more than 25 years, and has served in private practice and public health in towns as small as 1,900 residents and cities as large as 25 million. He has served as a local public health official and as the West Virginia Health Commissioner under two governors, where he brought together public health, law enforcement, healthcare, faith-based, business, and other community partners to solve local problems in novel and innovative ways. As the state’s Chief Health Officer, he led the opioid crisis response and launched a number of pioneering public health initiatives, including the Neonatal Abstinence Syndrome Birthscore program to identify high-risk infants, and the groundbreaking statewide Social Autopsy, which examined the lives of overdose victims to determine the factors that led to their deaths and what services could have prevented their deaths. Dr. Gupta has been recognized for his career of public service by the American Medical Association, the American Public Health Association, and by Governing Magazine, which named him their Public Health Official of the Year in 2018. Additionally, the Charleston Gazette-Mail named him as one of its West Virginians of the Year in 2017 for his service to the state. Dr. Gupta received his medical degree at the University of Delhi followed by subspecialty training in pulmonary medicine. He earned a master’s degree in public health from the University of Alabama-Birmingham and a global master’s of business administration degree from the London School of Business and Finance.

About V. Tyrone Lam
V. Tyrone Lam was appointed to the GATC Health Board of Advisors in May 2021, and as Chief Operating Officer in October 2021. He was appointed as Chief Business Officer in August 2024. He co-founded First Americans Health and Wellness, in October 2017, serving Native American and First Nations tribal members who suffer from diabetes and metabolic disorders from October 2017 until present. He has held various executive positions in the healthcare and entertainment/game television companies. Mr. Lam has a degree in political science and government from Virginia Tech University.

About Lin Yu, PhD
Lin Yu, PhD was Managing Director at Oppenheimer Healthcare Investment Banking until February 2023. Dr. Yu served a dual role as head of the firm’s Healthcare Royalty Monetization business and as an advisor for companies regarding equity capital markets strategies. He served as head of Medtech and then Life Science and Tools banking practices, working closely with seed-stage to publicly traded companies. Dr. Yu was directly involved in helping raise capital via equity, credit, royalty, and structured financing. Prior to joining Oppenheimer, he was a Managing Director at BTIG Healthcare Investment Banking. Previously, Lin was a Principal on the Healthcare Private Equity Team at KKR dedicated to its royalty and private credit strategy and a Director of Investment Research and Analysis at DRI Capital, a healthcare royalty-focused private equity firm. Earlier in his career, he was an Equity Research Analyst covering medical devices and technologies at Cowen & Co. Dr. Yu earned a Ph.D. and an M.S. from Columbia University in chemical engineering, where he focused his research on next-generation DNA sequencing technologies. He earned a B.S. in chemical engineering from The Cooper Union for Advancement of Science and Art.

About Tomas J. Philipson, PhD
Tomas J. Philipson, PhD is an economist who served as the Acting Chairman of the Council of Economic Advisers in the Trump administration. He departed from the position and the Council at the end of June, 2020, to return to the University of Chicago. He holds the Daniel Levin Chair in Public Policy at the University of Chicago, with posts in the Harris School of Public Policy Studies, Department of Economics, and the Law School. He was a Director of the Becker Friedman Institute at the university. Mr. Philipson received an undergraduate degree in mathematics from Uppsala University, and a Masters’ degree in Economics from Wharton followed by a PhD in Economics from the University of Pennsylvania where he won the William Carey Prize for Outstanding Dissertation in 1990. After receiving his PhD, he joined the University of Chicago as a postdoctoral fellow and thereafter joined the faculty. He has been a visiting faculty member at Yale University and a visiting fellow at The World Bank. Philipson served in the George W. Bush administration as the senior economic advisor to the Commissioner of Food and Drugs (the head of the Food and Drug Administration), and subsequently as the senior economic advisor to the head of the Centers for Medicare and Medicaid Services. Philipson is a co-founder of Precision Health Economics, a healthcare consulting firm that was headquartered in Los Angeles. It was sold in 2015. Philipson is a founding editor of the journal Forums for Health Economics & Policy of Bepress, and has been on the editorial board of the journal Health Economics and The European Journal of Health Economics. His research has been published widely in journals such as The American Economic Review, Journal of Political Economy, Quarterly Journal of Economics, Journal of Economic Theory, Journal of Health Economics, Health Affairs, and Econometrica. Philipson has twice received the Kenneth Arrow Award of the International Health Economics Association (for best paper in the field of health economics). In addition, he was awarded the Garfield Award by Research America, the Prêmio Haralambos Simeonidis from the Brazilian Economic Association, and the Distinguished Economic Research Award from the Milken Institute.

About Greg Sarafin
Greg Sarafin spent seven years as an executive at a multinational technology company prior to joining EY in 2015, running one of the top five accounts at the firm and then managing the professional services P&L for Banking and Financial Markets in North America. He also held significant leadership positions in financial service technology and digital disruption across industries. In addition, he helped found a health payments dot-com and, prior to that, ran his own software development company. Greg earned a BS in Computer Science and Engineering from the University of Pennsylvania.

About GATC Health
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.

833-333-GATC • info@gatchealth.com

GATC Health
Michael Tattory
mtattory@lifescicomms.com

Latest Legal Anabolic Steroid Alternatives for Bodybuilding 2026: Natural Steroids for Muscle Building & Cutting Fat Introduced by CrazyBulk

Latest Legal Anabolic Steroid Alternatives for Bodybuilding 2026: Natural Steroids for Muscle Building & Cutting Fat Introduced by CrazyBulk




Latest Legal Anabolic Steroid Alternatives for Bodybuilding 2026: Natural Steroids for Muscle Building & Cutting Fat Introduced by CrazyBulk

Legal Anabolic Steroid Alternatives for Bodybuilding from CrazyBulk in 2026: Best Selling Natural Steroids for Muscle Building and Cutting Fat.

New York City, NY, Dec. 04, 2025 (GLOBE NEWSWIRE) — In 2026, there is absolutely no need to use illegal anabolic steroids to build serious muscle growth, size, strength, and a lean, defined physique.

Modern natural muscle-building formulas support nitrogen retention, protein synthesis, performance, and fat burning using non-hormonal, legal ingredients.

This means you can confidently use the best legal steroids for muscle growth without touching your hormones or breaking the law. Whether your goal is to increase muscle mass, getting shredded, or cycling between the two, anabolic alternatives are built to support your bodybuilding results.

I’m Tony Stevens consultant at CrazyBulk – I’ve spent most of my life in the fitness industry; training, coaching, and helping lifters at every level build serious muscle and get lean the right way.

Steroid Alternatives Quick Look

Here are the most effective natural steroids for building muscle introduced by Crazy Bulk.

  • D-Bal as a Dianabol alternative
  • Tren-Max as a Trenbolone alternative

You can also combine with testosterone and deca to form a BULKING STACK – to accelerate your muscle gains.

Here are the best cutting steroids alternatives for shredding

You can add Win-Max (Winstrol alternative) to the mix and combine all three fat burning steroids to create a CUTTING STACK to get to your shredding targets quicker.

A few years ago, if you wanted truly dramatic results, people would tell you there were only two paths:

  • Grind it out naturally and accept “slow” results, or
  • Cross the line into anabolic androgenic steroids “performance enhancing drugs”.

But that era is over.

We’re heading into 2026, and with what we have available today, there is absolutely no need to use traditional anabolic steroids to build an impressive, powerful, lean physique. The industry has evolved – and the smartest athletes are evolving with it.

The New Choice: Muscle Gains Without Compromise

Instead of obsessing over the old “risk vs. reward” question around steroids, I want to flip the script and focus on what matters now:

How can you get powerful, noticeable, performance-enhancing results
while keeping your health, your hormones, and your life fully intact?

That’s exactly where natural, legal steroid alternatives shine.

Modern legal alternatives are designed so you don’t have to compromise:

  • You can still chase muscle mass, big strength and size goals.
  • You can still get shredded and stage-ready if that’s your aim.
  • You can do it all while staying within the law, and supporting your body rather than stressing it.

In 2026, with the science-backed formulations we now have access to, misusing anabolic steroids isn’t just unnecessary – it’s outdated thinking.

Authority Spotlight: Why I Trust CrazyBulk

Visit Crazy Bulk for latest offers on muscle building and cutting legal steroids

Over the years, I’ve been approached by a lot of supplement companies wanting an endorsement. Most of them I turned down. Why? Because when you look past the flashy labels, the formulas are usually underdosed, unproven, or just glorified caffeine pills.

CrazyBulk is different. And that’s why I’m comfortable putting my name next to theirs.

Here’s what matters to me—and why I recommend CrazyBulk as the gold standard and best legal steroid alternatives:

  • Pharmaceutical-grade standards
    Their products are manufactured in GMP-certified facilities, which means strict quality control, consistent dosing, and clean, reliable ingredients.
  • Non-hormonal, natural formulas
    No synthetic hormones, no banned substances. That means no hormonal shutdown, no need for PCT, and no endocrine “rollercoaster” when you stop taking them.
  • Targeted, purpose-built products
    They don’t hide behind vague “muscle boosters.” Each product is built as a specific alternative to a well-known steroid:
    • D-Bal as a Dianabol alternative
    • Tren-Max as a Trenbolone alternative
    • Deca-Max as a Deca-Durabolin alternative
    • Clenbutrol as a Clenbuterol alternative
    • Anvarol as an Anavar alternative
    • Win-Max as a Winstrol alternative
  • That means you can build bulking, cutting, or strength-focused stacks with a clear purpose behind every capsule.
  • Real-world results
    I’ve seen natural lifters use CrazyBulk products to:
    • Add lean mass while staying relatively lean
    • Hold onto muscle during an aggressive cut
    • Increase strength and training volume without burning out

No, you’re not going to gain 25 pounds of pure muscle in a month—and you shouldn’t want to. What you will get is steady, sustainable, noticeable improvement that doesn’t come with a health bill later.

From my perspective as a coach and an expert on safe, legal alternatives, this is what the new era of anabolic gains looks like:

  • You still push heavy.
  • You still diet hard.
  • You still earn every pound of muscle and every line of definition.

But now, you can amplify those efforts with products that respect your body, your health, and your future.

That’s why, when people ask me how to get “steroid-like” results without actually taking steroids, my answer is simple:

Get your training and nutrition right—
then use CrazyBulk’s legal steroid alternatives to take those results as far as your genetics and work ethic will allow,
safely and legally.

What Are Legal Steroid Alternatives? Defining the Natural Steroids Niche

When I talk about legal steroid alternatives, I’m not talking about “watered-down steroids” or shady grey-area products. I’m talking about fully legal, non-hormonal formulas designed to give you a real performance and physique edge by supporting the same key processes that drive muscle growth, strength, and fat loss—without ever touching your endocrine system.

These natural alternatives work by targeting the mechanisms that actually matter for body composition: nitrogen retention, protein synthesis, energy output, and thermogenesis

By improving nitrogen retention, they help keep your muscles in an anabolic, growth-focused state. 

By supporting protein synthesis, they help your body turn the protein you eat into actual muscle tissue more efficiently. 

Many also enhance training performance and metabolic rate, so you can push harder in the gym and burn more fat, even at rest. The result is a steroid-style advantage in the gym, but powered by natural pathways, not synthetic hormones.

From a safety and regulatory standpoint, this is where they really separate themselves from illegal gear. 

Legal steroid alternatives are built from natural, non-hormonal ingredients, produced in GMP-certified facilities under strict quality control. 

No injections, no controlled substances, no PCT needed. That makes them ideal for serious bodybuilders, powerlifters, and athletes who want lean mass, strength, or fat loss—but refuse to wreck their health or risk their career for it.

Most Effective Natural Steroids for Muscle Building (Bulking Focus)

When you’re in a true bulking phase, your goal is simple: add quality size and strength as fast as your body can realistically handle it – without just getting fat or wrecking your joints. 

This is where the right legal steroid alternatives can make a huge difference, especially if your training and nutrition are already locked in. 

CrazyBulk’s bulking line is designed to mimic the benefits of classic mass-building steroids using natural, non-hormonal formulas that support growth, performance, and recovery from multiple angles.

D-Bal (Dianabol Alternative): The Ultimate Mass and Strength Builder

D-Bal is built to be your foundational bulking steroid

D-Bal’s main aim is maximizing nitrogen retention, which is critical for keeping your muscles in a more anabolic state. Better nitrogen balance means you can use more of the protein you eat to build and repair muscle, leading to faster size and strength gains. In a proper bulk, D-Bal helps you feel fuller, stronger, and more explosive under the bar.

Tren-Max (Trenbolone Alternative): Power, Conditioning, and Vascularity

Tren-Max is all about power and density. Its standout benefit is supporting red blood cell production, which improves oxygen delivery to your muscles. That translates into harder sets, stronger lifts, better conditioning, and increased vascularity as you grow. It’s ideal for lifters who want a hard, athletic look while still adding size.

Proven Legal Steroids for Cutting Fat and Definition (Cutting Focus)

A proper cutting phase isn’t just about watching the scale drop—it’s about getting lean without sacrificing the muscle and strength you worked so hard to build. 

The goal is sharper lines, tighter skin, and visible separation between muscle groups, while still performing well in the gym. 

This is where cutting-focused legal steroid alternatives from CrazyBulk can give you a serious edge, helping you burn more fat, maintain muscle, and bring out definition.

Clenbutrol (Clenbuterol Alternative): Thermogenic Fat Incineration

Clenbutrol is designed to turn your body into a more efficient fat-burning machine

Clenbutrol’s key benefit is increasing core temperature, which naturally boosts your metabolism. A slightly higher internal temperature means you burn more calories throughout the day—even at rest. On top of that, Clenbutrol supports clean, usable energy for your workouts, so you can still train with intensity while eating fewer calories and leaning out.

Anvarol (Anavar Alternative): Lean Muscle Retention and Energy

Anvarol is your muscle-protection insurance policy during a cut. When calories drop, your body is tempted to use muscle tissue as fuel. 

Anvarol’s key benefit is maintaining strength and helping prevent muscle catabolism during calorie deficits. It supports ATP production (your muscles’ immediate energy source), helping you stay strong, explosive, and “tight” even as body fat comes down.

Win-Max (Winstrol Alternative): Hardening and Vascularity

Win-Max is all about the final look—that dry, hard, detailed appearance. Its key benefit is helping you achieve a shredded, competition-ready physique, enhancing muscle hardness and vascularity when your body fat is already on the lower side. 

Used toward the sharper end of a cut, Win-Max helps bring out definition in the shoulders, arms, and quads, making every line and vein more visible under good lighting. Combined, Clenbutrol, Anvarol, and Win-Max give you a complete, natural cutting arsenal.

Effective Natural “Steroid” Alternatives

Over the last several years, we’ve entered a completely different era – one where you don’t have to choose between big muscle definition and your health.

This is where natural steroid alternatives, often called “legal steroids,” come in.

Now, to be clear:
These are not anabolic steroids. They don’t contain hormones. They don’t need injections. They don’t require PCT (post-cycle therapy).

Instead, they’re advanced, targeted formulas built from natural, legal ingredients designed to:

  • Boost nitrogen retention so your muscles stay in an anabolic (growth) state
  • Support protein synthesis, helping your body build and repair muscle more efficiently
  • Enhance energy, strength, and performance during training
  • Increase thermogenesis, helping your body burn more calories and fat
  • Improve recovery, so you can train harder and more often

In other words, they’re engineered to mimic the positive effects of illegal steroids—
without hijacking your hormones, damaging your organs, or putting you on the wrong side of the law.

When I talk about “legal steroids,” I’m talking about a smarter path:

  • 100% legal
  • 100% natural formulas
  • Designed to deliver real, visible progress to support muscle growth, strength, and fat loss
  • Built for long-term, sustainable progress—not a 6–8 week blast followed by a crash

If you’re serious about your physique but refuse to gamble with your health, this is the lane you should be in.

The Crucial Question: Are Legal Alternatives as Effective as Illegal Anabolic Steroids?

This is the question I get asked the most, and I’ll answer it honestly: legal steroid alternatives are not identical to illegal anabolic steroids—and that’s actually their biggest strength.

Performance Comparison: What Results Can You Really Expect?

If you’re expecting the kind of extreme, rapid weight jumps that come from heavy steroid cycles, you’re going to be disappointed—and you should be. 

Those “10–20 pounds in a few weeks” transformations are usually a mix of water retention, drug-driven glycogen storage, and a hormonal rollercoaster that always carries a cost.

Legal alternatives like CrazyBulk products are designed for steady, noticeable, and realistic progress:

  • Solid increases in strength and training volume
  • Visible improvements in muscle fullness and density
  • Better fat loss and definition when cutting

You won’t wake up “mutant big” in 30 days—but you will build a physique that looks powerful, athletic, and natural, without crashing afterward.

Sustainability and Longevity

The real advantage of legal alternatives is what happens after the bottle is empty. Because they’re non-hormonal, your body doesn’t experience shutdown, rebound fat gain, or post-cycle depression. 

You can run them for multiple cycles across the year, keep your routine consistent, and hold onto your gains as long as you keep training and eating properly. That’s something most steroid users quietly struggle with.

Side Effect Trade-off: Health First

With legal steroids, you’re choosing results without the collateral damage. No liver toxicity, no gyno, no testicular shrinkage, no hormonal crash that forces you into PCT. For me as a coach, that trade-off is simple: slightly slower, safer progress that you can actually live with beats dangerous, unstable “all-or-nothing” cycles every time.

The Power of Synergy: CrazyBulk’s Stack Strategy

One of the biggest mistakes I see lifters make is treating supplements like random add‑ons instead of a coordinated system

The real advantage of CrazyBulk isn’t just the individual products—it’s how they’re designed to work together in targeted stacks for bulking and cutting. When you combine the right legal steroids, you don’t just add benefits; you multiply them.

The Ultimate Bulking Stack: Maximum Mass and Strength

For serious size and strength, I recommend a bulking stack built around D-Bal + Tren-Max + Deca-Max. D-Bal focuses on nitrogen retention and protein synthesis, giving you the core muscle-building engine. 

Tren-Max adds raw power, conditioning, and density, helping you push heavier loads and handle more volume. Deca-Max supports joint comfort and recovery, so your tendons and connective tissue can keep up with your heavier training. Together, this stack helps you train harder, recover faster, and add quality mass without feeling beat up.

The Ultimate Cutting Stack: Rapid, Lean Fat Loss

When it’s time to lean out, a cutting stack like Clenbutrol + Anvarol + Win-Max covers all bases. 

Clenbutrol drives thermogenesis and metabolic output, helping your body burn more calories and fat. 

Anvarol supports muscle retention and strength in a calorie deficit, so you stay strong instead of flat and weak. 

Win-Max sharpens hardness, definition, and vascularity, especially as body fat gets lower. This combo helps you get lean, tight, and detailed—not just smaller.

Cycle Optimization: How to Run a Stack for 4–8 Weeks

For most lifters, a 4–8 week cycle is ideal. Run your chosen stack daily, with consistent timing (often split across the day, and some caps pre-workout), and align it with a clear goal: calorie surplus and progressive overload for bulking, or a controlled deficit and higher output for cutting. 

Four weeks is enough to feel clear changes in strength, energy, and composition; eight weeks lets you lock in those results. Because these are non-hormonal, you don’t need PCT—just smart transitions between bulk, maintenance, and cut, with brief deloads if needed.

Safety First: The Zero Side-Effect Promise of Natural Steroids

One of the biggest advantages of CrazyBulk’s legal steroid alternatives is how they’re built from the ground up with safety and consistency in mind. 

In the modern legal steroid market, these are among the most popular legal steroids because they behave like legal bodybuilding supplements, not drugs. 

Every formula is produced in GMP-certified facilities, which means strict quality control, clean ingredient sourcing, and precise dosing in every batch. 

Just as important, these legal supplements are 100% non-hormonal, so they don’t shut down your natural testosterone, don’t boost testosterone artificially, and don’t disrupt your endocrine system. 

That’s why there’s no need for PCT (Post Cycle Therapy)—you don’t experience hormonal crashes, mood swings, or “post-cycle” fat gain. 

You simply stop when your cycle ends, keep training, and maintain lean muscle mass, muscle definition, and lower body fat the natural way.

Legal Anabolic Steroids User Guide: Dosage, Timing, and Expected Cycle Length

Each CrazyBulk product in the popular legal steroids range comes with a clear daily dosage, typically spread across the day with some capsules taken about 30–45 minutes before your workout for maximum athletic performance benefits. 

These legal steroid alternatives designed to enhance muscle growth, support muscle definition, and help reduce body fat work best when used consistently. 

Most users run a 4–8 week cycle, depending on whether they’re bulking for more lean muscle mass or cutting to tighten up and drop body fat

But none of this works in isolation. To see real results from the best legal steroid alternative stacks, you must pair these legal bodybuilding supplements with a disciplined diet, progressive strength training, adequate sleep, and consistent effort in the gym.

Authority and Social Proof: Why CrazyBulk Leads the Market

Within the legal steroid market, CrazyBulk stands out as one of the most popular legal steroids brands because its reputation wasn’t built on hype; it was built on real-world results

Across thousands of testimonials, users report noticeable muscle gain, strength increases, improved athletic performance, and significant body fat loss during cutting phases, often with visible improvements in muscle definition and overall lean muscle mass within a few weeks of consistent use. 

Many lifters consider their stacks the best legal steroid alternative approach for those who want to enhance muscle growth and stay natural. 

That track record is backed by a strong money-back guarantee, which shows the brand’s confidence in its formulas and respect for the customer. If you’re not satisfied, you’re protected—something you’ll never get with underground, illegal anabolic steroids.

Conclusion: Building Your Best Body Safely with Legal Steroids

Legal steroid alternatives give modern athletes the sweet spot: real gains in muscle, strength, and fat loss without hormonal risk, legal issues, or post-cycle crashes. 

If you’re serious about transforming your physique safely, visit the official CrazyBulk website for the best pricing, bundles, and goal-focused stacks.

Frequently Asked Questions about CrazyBulk Legal Steroids

1. Are CrazyBulk products real steroids?
No. CrazyBulk products are legal steroid alternatives made from natural, non-hormonal ingredients. They’re designed to support muscle growth, strength, and fat loss without acting like illegal anabolic steroids.

2. What is the best legal steroid alternative for overall muscle growth and cutting fat?
For a single all-rounder, many users rate D-Bal as the best legal steroid alternative for building lean muscle and improving body composition. For maximum results, use it as part of a bulking or cutting stack.

3. Are legal bodybuilding supplements like CrazyBulk safe?
Yes. CrazyBulk formulas are produced in GMP-certified facilities, using natural ingredients and no hormones. They don’t cause liver damage, gyno, or hormonal crashes associated with illegal gear.

4. Will these legal steroids help with muscle definition and body fat loss?
Yes. Cutting products like Clenbutrol, Anvarol, and Winsol are designed to increase thermogenesis, protect lean muscle mass, and help reduce body fat while improving muscle definition.

5. How long before I see results with CrazyBulk?
Most users notice better strength, energy, and visual changes in 2–4 weeks, with the best results over a full 4–8 week cycle, combined with strict diet and training.

6. Do I need PCT (Post Cycle Therapy) after CrazyBulk cycles?
No. These are non-hormonal legal supplements, so they don’t suppress your natural testosterone. You can stop after a cycle without PCT or hormonal “crash.”

7. Can CrazyBulk help enhance athletic performance, not just looks?
Yes. Many products are formulated to support strength, endurance, recovery, and power, making them ideal for athletes who want performance plus better physique.

8. What’s the best stack for lean muscle mass and minimum fat gain?
For clean, lean gains, a popular choice is a recomposition-style stack: D-Bal (size and strength), Trenorol (power and conditioning), and Anvarol (muscle retention and energy).

9. Are CrazyBulk legal steroids suitable for beginners?
Yes. They’re ideal for natural lifters, beginners, and intermediates who want faster progress without health risks. Just follow the label dosage and stick to a proper program.

10. Where should I buy CrazyBulk to get the best deal and avoid fakes?
Always buy from the official CrazyBulk website for authentic products, best pricing, bundle discounts, and the full money-back guarantee.

Media Contact:
Tony Stevens, Head of Product Innovation
CrazyBulk
244 Madison Avenue, New York City, NY 10016-2817
Email: support@crazybulk.com
Phone: +1 888-708-6394
Website: https://crazybulk.com

Attachment

CONTACT: Media Contact:
Tony Stevens, Head of Product Innovation
CrazyBulk
244 Madison Avenue, New York City, NY 10016-2817
Email: support@crazybulk.com
Phone: +1 888-708-6394
Website: https://crazybulk.com